Monday, 18 Feb 2019

You are here

Vertebroplasty and Kyphoplasty Shown to Be Ineffective

There are approximately 750,000 new vertebral compression fractures each year in the United States, with resultant acute and chronic back pain in over one‐third of patients with vertebral fractures (VF).  Both percutaneous vertebroplasty or balloon kyphoplasty have been advocated as useful means of restoring vertebral height and strength capable of reducing pain in symptomatic patients. Balloon kyphoplasty is currently more expensive and is performed almost three times more commonly than percutaneous vertebroplasty in the United States

The American Society for Bone and Mineral Research (ASBMR) has established a Task Force to address the efficacy and safety of vertebral augmentation and other approaches for the treatment of vertebral compression fracture as there is a lack of consensus regarding efficacy and safety of percutaneous vertebroplasty and kyphoplasty.

For patients with acutely painful VF, percutaneous vertebroplasty provides no demonstrable clinically significant benefit over placebo.

Results did not differ according to duration of pain.

There is also insufficient evidence to support kyphoplasty over nonsurgical management, percutaneous vertebroplasty, vertebral body stenting, or KIVA®.

There is limited evidence regarding the risk of incident VF or other serious adverse effects (AE) related to vertebroplasty or kyphoplasty.

In those with symptomatic painful VF:

  • Unclear whether spinal bracing improves physical function, disability, or quality of life.
  • Exercise may improve mobility and may reduce pain and fear of falling but does not reduce falls or fractures in individuals with VF.

There is considerable need to reduce study bias and address methodological flaws seen in these studies. This includes the need for larger sample sizes, inclusion of a placebo control, more data on serious AE, and more research on nonpharmacologic interventions.

Thus routine use of vertebral augmentation is not supported by current evidence and patients should be fully informed about the evidence.

Lastly, other anti‐osteoporotic medications have been show to reduce the risk of subsequent vertebral fractures by 40–70%. 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Older Men Less Likely to be Assessed and Treated for Osteoporosis

A study from the University of Washington in Seattle find that men with osteoporosis were less likely to be assessed by dual-energy X-ray absorptiometry (DXA); vitamin D measurements and were less like to receive calcium/vitamin D and bisphosphonate prescriptions. 

Hip Replacements Lasting 25 Years

Lancet reports that, based on a literature review and metanalysis, patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

In the USA, there is an estimated 400,000 total hip arthroplasties (THA) annually. UK invesigators set out to answer the question: how long does a hip replacement last?

Opioid Use in Osteoarthritis Varies by State

A study in Arthritis & Rheumatology shows that there is substantial statewide variation in rates of treatment with long‐term opioid therapy in osteoarthritis - not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.

FDA Panel Backs Approval of Romosuzumab for Osteoporosis

The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis. 

Reuters reports that the panel voted 16-1 in favor of the monthly injection developed jointly by UCB.

Heberden’s Nodes Predict Knee OA Progression

Hand and knee osteoarthritis are considered to be clinically and pathogenically different and distinct, but a new study suggests that Heberden's nodes (HNs) can predict MRI‐based knee osteoarthritis (OA) progression.

An NIH study of 575 subjects included clinical examination with evaluation of HNs at baseline and knee MRI at baseline and 24‐month.